ESR1 and breast carcinoma: The repurposing of existing FDA-approved NSAIDs and anti-parasitic drugs that suppress Wnt/β-catenin signaling is emerging as a more promising clinical strategy [120], such as pyrvinium which was selectively cytotoxic to INPP4B-overexpressing ER+ breast cancer cells in combination with 4-OHT [102].